Upstream Bio(UPB.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Upstream Bio
UPB.US
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
1.927 T
UPB.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking94/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-124.45%E
    • Profit Margin-4366.77%E
    • Gross Margin100.00%A
  • Growth ScoreB
    • Revenue YoY26.82%A
    • Net Profit YoY-140.18%E
    • Total Assets YoY68.11%A
    • Net Assets YoY71.64%A
  • Cash ScoreB
    • Cash Flow Margin-2.06%D
    • OCF YoY26.82%A
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio3.22%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NIH Says Policy Shift To End Use Of Human Fetal Tissue In NIH-Supported Research

    Jan 22 (Reuters) - NIH:* NIH: POLICY SHIFT TO END USE OF HUMAN FETAL TISSUE IN NIH-SUPPORTED RESEARCH* NIH: EFFECTIVE IMMEDIATELY, NIH FUNDS WILL NO LONGER BE USED TO SUPPORT RESEARCH INVOLVING HUMAN FETAL TISSUE FROM ELECTIVE ABORTIONS

    Reuters·
    Reuters·

    These Are Today’s Marketing Moving Trades

    Investors are moving away from consumer packaged goods, with Berkshire Hathaway planning to sell its 27.5% stake in Kraft Heinz, which saw a 6% drop in stock price. Applovin and Oracle are also trending down, while Microsoft faces criticism over Windows 11. In contrast, Intel's stock is rising ahead of its quarterly results, and Sandisk has gained 10.5% recently. Moderna's share price is nearing a double, with significant short interest.

    Baystreet·
    US
    BRK.B
    -0.27%
    US
    SNDK
    -0.86%
    US
    MRNA
    +10.42%
    Baystreet·
    US
    BRK.B
    -0.27%
    US
    SNDK
    -0.86%
    US
    MRNA
    +10.42%

    ICRF and CRI co-fund grant to address immunotherapy resistance in melanoma led by Asaf Madi, PhD. – Tel Aviv University.

    A recent study overseen by Dr. Asaf Madi from Tel Aviv University aims to enhance the effectiveness and longevity of TIL therapy for individuals facing advanced illnesses. In an announcement made on January 22, 2026, in New York, the Israel Cancer Research Fund (ICRF) and the Cancer Research Institute (CRI) disclosed their collaboration on a fresh award. This initiative seeks to boost the reliability and durability of TIL therapy for patients, highlighting the commitment to advancing cancer treatment options.

    Unusual Whales·
    Unusual Whales·

    FACTBOX-How four US childhood vaccine recommendations have changed

    The Trump administration has revised childhood vaccine recommendations, shifting from universal vaccination to shared decision-making between parents and healthcare providers for influenza, rotavirus, meningococcal disease, and hepatitis A. Major medical organizations oppose these changes, warning of increased infections and hospitalizations. The CDC's new guidelines reflect a lack of consensus on universal vaccination and aim to align with practices in other wealthy countries. Despite the changes, leading health authorities continue to advocate for these vaccines to protect public health.

    Reuters·
    Reuters·

    FOCUS-Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality

    U.S. Health Secretary Robert F. Kennedy Jr.'s anti-vaccine policies are causing frustration among vaccine makers, leading to decreased vaccination rates and valuation pressures for biotech firms. The administration's changes, including the end of broad vaccine recommendations, have raised concerns about public health and investor confidence. Major companies like Pfizer and Sanofi have publicly criticized Kennedy's rhetoric, which they believe undermines scientific merit. While long-term prospects for vaccines remain strong, political influences are complicating the investment landscape for smaller biotech firms.

    Reuters·
    Reuters·
    © 2026 Longbridge｜Disclaimer